News – Jan 22, 2018

Jennifer Hart joins Julius Clinical

We are pleased to announce that Jennifer Hart has joined our company as Executive Director Business Development North America. In her new role as Executive Director, Ms. Hart will oversee the North American Business Development efforts for Julius Clinical and Cohortias, a joint venture between Julius Clinical and Zumanis.

Ms. Hart has close to 20 years’ experience in the pharmaceutical and clinical research industries, serving roles as a chemist, leading Quality Assurance audits and CAPA proceedings and many years of sales and marketing experience in the clinical research industry.

Trained as an analytical chemist, Ms. Hart not only brings scientific expertise to her role in Business Development, but also a wealth of relationships with US  Key Opinion Leaders  in the areas of Psychiatry, Neurology, Cardiology and Infectious Disease which she has built throughout her career.

Aize Smink, CEO Julius Clinical: “We are very fortunate to have Jennifer on our team. Strategically, the US is important for Julius Clinical with a significant number of existing and future potential clients in the territory.  Jennifer's extensive connections and relationships with small and large pharma and biotech companies in the US, as well as her deep understanding of the US market, will prove invaluable for Julius as we continue to grow.  Jennifer will also be a significant asset in commercially advancing our joint venture in Latin America, Cohortias.  We are very excited and positive about the future.”

Ms. Hart will be based in Durham, North Carolina.